http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Paolo Scollo (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Genetic screening in young women diagnosed with endometrial cancer
Basilio Pecorino,Cinzia Rubino,Vito Fabio Guardalà,Antonio Galia,Paolo Scollo 대한부인종양학회 2017 Journal of Gynecologic Oncology Vol.28 No.1
Objective: To evaluate the importance of Lynch syndrome associated risk screening in the patients aged less than 50 years affected from endometrial cancer. Methods: From 2007 to 2014, 41 patients affected from endometrial cancer and aged less than 50 years underwent surgery at the Complex Operative Unit of Gynecology and Obstetrics, Cannizzaro Hospital of Catania, Italy. They were selected to undergo mismatch repair gene mutation analysis using immunohistochemistry (IHC; four markers: MLH1, MSH2, MSH6, PMS2) and microsatellite instability (MSI) test. For samples that resulted negative to IHC (abnormal finding), MSI test was performed to further study the suspected mutation. Samples were classified as MSI-high (MSI-H) if more than one marker was identified as unstable; MSI-low (MSI-L) if only one marker was identified as unstable; or MSI-stable (MSI-S) if no marker was identified as unstable. Samples were subdivided into two groups: MSI-H/L and MSI-S. Statistical analysis was performed to assess differences regarding survival, tumor staging, grading, and invasion of lymphovascular space between these two groups. Results: IHC analysis showed that in 46% (19/41) of samples there was negative outcome. Forty-two percent (8/19) of these negative samples were unstable (either low or high). Of eight patients showing MSI, 75% were MSI-L, while 25% were MSI-H. Differences in survival, stage, grade, lymphovascular space invasion and Amsterdam criteria adherence were not statistically significant due to the small size of the cohort. Conclusion: IHC and MSI test results of our cohort lead us to assess the relevance of performing Lynch syndrome genetic screening in endometrial cancer patients aged less than 50 years at the time of diagnosis.
-
Giuseppa Scandurra,Giuseppe Scibilia,Giuseppe Luigi Banna,Gabriella D’Agate,Helga Lipari,Stefania Gieri,Paolo Scollo 대한부인종양학회 2015 Journal of Gynecologic Oncology Vol.26 No.2
Objective: To evaluate the efficacy and tolerability of a neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy inpatients with locally advanced cervical carcinoma. Methods: Patients with histologically confirmed locally advanced cervical carcinoma, aged ≥18 years, were treated withintravenous ifosfamide 5,000 mg/m2 and mesna 5,000 mg/m2, on day 1; intravenous paclitaxel 175 mg/m2 and cisplatin 75 mg/m2, on day 2; every 3 weeks for three cycles. Following chemotherapy, operable patients underwent radical hysterectomy andpelvic lymphadenectomy, and, if necessary, adjuvant radiotherapy. Results: One hundred fifty-two patients with median age 53 years (range, 24 to 79 years), FIGO stage IIB in 126 (89%), weretreated with chemotherapy for median 3 cycles (range, 1 to 3). Treatment was delayed or withdrawn in 23 patients (15%). Onehundred thirty-nine patients (91%) underwent surgery. Postchemotherapy pathological complete response rate was 18% (25patients). Postoperative radiotherapy was administered in 100 patients (72%). The 5-year overall survival and progression-freesurvival were 87.3% (95% confidence interval [CI], 84.5 to 90.3) and 76.4% (95% CI, 73.5 to 79.5), respectively. Conclusion: Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy was feasible and effective in the treatment oflocally advanced cervical carcinoma patients with older age and more advanced disease stage than reported in previous studies. Hematological and renal toxicity could be carefully prevented.
-
Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups
Giorgio Bogani,Giovanni Apolone,Antonino Ditto,Giovanni Scambia,Pierluigi Benedetti Panici,Roberto Angioli,Sandro Pignata,Stefano Greggi,Paolo Scollo,Mezzanzanica Delia,Massimo Franchi,Fabio Martinell 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.6
Objective: Coronavirus disease 2019 (COVID-19) has caused rapid and drastic changesin cancer management. The Italian Society of Gynecology and Obstetrics (SIGO), andthe Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO)promoted a national survey aiming to evaluate the impact of COVID-19 on clinical activity ofgynecologist oncologists and to assess the implementation of containment measures againstCOVID-19 diffusion. Methods: The survey consisted of a self-administered, anonymous, online questionnaire. The survey was sent via email to all the members of the SIGO, and MITO groups on April 7, 2020,and was closed on April 20, 2020. Results: Overall, 604 participants completed the questionnaire with a response-rate of70%. The results of this survey suggest that gynecologic oncology units had set a proactiveapproach to COVID-19 outbreak. Triage methods were adopted in order to minimizein-hospital diffusion of COVID-19. Only 38% of gynecologic surgeons were concernedabout COVID-19 outbreak. Although 73% of the participants stated that COVID-19 hasnot significantly modified their everyday practice, 21% declared a decrease of the use oflaparoscopy in favor of open surgery (19%). However, less than 50% of surgeons adoptedspecific protection against COVID-19. Additionally, responders suggested to delay cancertreatment (10%–15%), and to perform less radical surgical procedures (20%–25%) duringCOVID-19 pandemic. Conclusions: National guidelines should be implemented to further promote the safety ofpatients and health care providers. International cooperation is of paramount importance,as heavily affected nations can serve as an example to find out ways to safely preserve clinicalactivity during the COVID-19 outbreak.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
